Biotech Startups

Nourish Ingredients uses precision fermentation and lipid biotechnology to make animal-free fats and flavor ingredients, including Tastilux (a meaty phospholipid flavor) and Creamilux (a dairy emulsifier), for use in alternative meat and plant-based or hybrid dairy products. It sells these high-potency fat solutions to global food companies and brands developing animal-free foods.

1 investor

NovaFlow is an AI-powered data analysis platform that automates bioinformatics workflows for life science researchers and biotech labs, transforming raw experimental data into publication-ready results in minutes using large language models and validated computational pipelines.

1 investor

NovaGo Therapeutics is a biotech company developing antibody-based therapeutics to promote nerve repair and recovery following spinal cord injury. The company's candidates are designed to enhance nerve regeneration and functional recovery, with Phase 1 clinical trials expected to begin in 2024.

1 investor

Novamab (上海洛启生物医药) is a clinical-stage biopharmaceutical company developing VHH (nanobody) antibody drugs for respiratory and inflammatory diseases, with pipelines including inhaled, oral, and bi/multi-specific antibody platforms targeting asthma, COPD, and inflammatory bowel disease. Based in Shanghai, its drug candidates address indications such as IL-4Rα, TSLP, and TL1A.

1 investor

Numinus provides psychedelic-assisted therapy and mental health treatment, focusing on preparation, guided experiences, and post-session integration for individuals. It positions psychedelics as medicines requiring careful clinical support rather than standalone treatments.

1 investor

Novapep is an Australian-US biotech company developing G10, a polypeptide agonist that mimics activated protein C signaling to reduce inflammation. The company focuses on peptide-based therapeutics for inflammatory and infectious diseases.

1 investor

Novaurum Biosciences develops nanotechnology-based coatings for medical devices and implants, using atomic layer deposition and a proprietary cell-based coating to improve biocompatibility, reduce infection, and support tissue integration. It serves medical device manufacturers, working at the intersection of microbiology and materials science.

1 investor

Novel Care accelerates the development and deployment of new medical treatments by bringing together clinicians, technologists, and designers. The company works with research and healthcare organizations to bridge healthcare and scientific research.

1 investor

Novellus operates a technology platform for securities lending that lets institutional participants transact directly on a principal-to-principal basis, covering the full lifecycle including settlement and collateralization. It targets institutional market participants looking to in-source securities lending workflows.

1 investor

Novilla develops localized medicines designed with proprietary chemical-thermodynamics machine learning algorithms, delivering drugs that act at the site of disease while minimizing systemic exposure and side effects. The company focuses on pain therapeutics, aiming to provide effective treatments without the addiction risks associated with opioids.

1 investor

Novilytic develops a simplified analytical testing system using a single HPLC instrument with fluorescence detection and proprietary Proteometer Kit to replace multiple instruments and personnel traditionally required for R&D analytical work in chemistry.

1 investor

Novobiom develops fungi-based biotechnology solutions for soil remediation, waste management, and sustainable production. The company uses mycoremediation and biomimicry to address environmental challenges such as soil contamination, plastic breakdown, and textile waste recycling.

1 investor

NovoClade develops biological technologies, using organismal biology and computational design, to control invasive species that threaten agriculture, livestock, and ecosystems. Its platform selects GM or non-GM intervention formats based on the target species and deployment context, serving agricultural, animal agriculture, and ecological pest-control applications.

1 investor

Novonesis develops biological solutions for agriculture, animal feed, food production, and consumer products, helping customers improve crop yields, product quality, and sustainability. The company applies microbial and enzyme-based technologies to address food system challenges and reduce environmental impact across multiple industries.

1 investor

NovoPedics is developing MeniscoFix, a resorbable implant placed via arthroscopically-assisted surgery to replace the entire medial or lateral meniscus of the knee, intended to relieve pain, restore mobility, and prevent osteoarthritis in patients with severe meniscal injuries. The device has received FDA Breakthrough Device Designation and supports the growth of new meniscus-like tissue as it resorbs.

1 investor

Novo Protein supplies GMP-grade mRNA enzymes, reagents, and diagnostic materials for biopharmaceutical research and production, including reagents for in vitro transcription, molecular diagnostics, gene editing, and immunoassay development.

1 investor

1 investor

Novoron develops lipoprotein-receptor small molecule therapies aimed at repairing damage and degeneration of the brain and spinal cord, including treatments for proteinopathies and neuroregeneration following traumatic injury. The company focuses on drug discovery for neurological conditions such as neurodegeneration and cognitive decline.

1 investor

NOVUSON develops biomedical instrumentation and medical devices, serving healthcare organizations and clinical environments. The company focuses on innovative medical technology across biomechanics, tissue engineering, and surgical device platforms.

1 investor

NovusTX Devices develops therapeutic ultrasound technology for clinical medical applications, particularly focusing on minimally invasive brain therapies using HIFU (high-intensity focused ultrasound). The company emerged from research collaboration at the Thunder Bay Regional Health Research Institute and the University of Calgary.

1 investor

nPhyla is a biotechnology company that uses environmental DNA (eDNA) and analytics to provide site-level biodiversity assessments, microbial screening, and reporting tools for mining companies. It serves mining operators, researchers, and regulators to support ecosystem monitoring, reclamation, and sustainability requirements, with samples drawn from mine sites across North America.

1 investor

NRGene leverages genomic data and AI to optimize crop development and breeding for sustainable agriculture. The company serves seed companies, agricultural producers, and agronomic organizations seeking to improve food security through data-driven plant genetics.

1 investor

NRx Pharmaceuticals develops medicines for people with unmet medical needs, focused on making untreatable diseases treatable. It operates in the pharmaceutical and biotech industry.

1 investor

Nordic Science Investments is an early-stage venture capital fund that invests in science-based startups and university spinouts across the Nordic region, with a focus on deeptech, health tech, and life sciences. The fund works with leading regional universities to commercialize frontier research and tackle global challenges.

1 investor